Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Ali Bazarbachi, Myriam Labopin, Nour Moukalled, Nicolaus Kröger, Christina Rautenberg, Johannes Schetelig, Jürgen Finke, Igor Wolfgang Blau, Didier Blaise, Matthias Stelljes, Matthias Eder, Uwe Platzbecker, Peter Dreger, Wolfgang Bethge, Johanna Tischer, David Burns, Henrik Sengeloev, Eolia Brissot, Sebastian Giebel, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
PURPOSE: Acute myeloid leukemia (AML) is a disease of older patients. Progress in allogeneic hematopoietic cell transplantation (allo-HCT) allowed the delivery of allo-HCT to older patients. We assessed changes over time in transplant characteristics and outcomes in patients with AML ages 65 years and above. PATIENTS AND METHODS: We identified 7,215 patients with AML (median age 68 years, range 65-80) allografted between 2000 and 2021 in first complete remission (CR1; 64%), second or subsequent remission (CR2+; 14%), or active disease (22%)...
March 22, 2024: Clinical Cancer Research
#22
JOURNAL ARTICLE
Mohamed Yehia Hamdy, Hayam El Aggan, Iman El Gohary, Ahmed Halawa
OBJECTIVES: Elderly renal transplant continues to be debated because of age-related factors affecting transplant success and long-term prognosis. We investigated the effects ofrecipient age and predictors of renal transplant outcomes in elderly renal transplant recipients. MATERIALS AND METHODS: We retrospectively analyzed 506 patients who had a first renal transplant between January 2010 and December 2020; there were 165 recipients aged ≥60 years (elderly) and 341 recipients aged <60 years (young)...
February 2024: Experimental and Clinical Transplantation
#23
JOURNAL ARTICLE
Guillermo Garcia-Manero, Maciej Kazmierczak, Agnieszka Wierzbowska, Chun Yew Fong, Michael K Keng, Gianluca Ballinari, Francesco Scarci, Lionel Adès
Non-intensive therapies such as the hypomethylating agent (HMA) azacitidine (AZA) have been used in patients with AML ineligible for intensive induction chemotherapy (IC) or stem cell transplant due to advanced age, comorbidities, and/or risk factors. However, response rates and survival remain dismal. Pre-clinical studies indicate the epigenetic combination of HMAs and HDAC inhibitors induce re-expression of silenced genes synergistically. The activity of pracinostat, an oral pan-HDAC inhibitor, has been shown in xenograft tumor models of AML and promising efficacy was seen in a Phase 2 study...
March 12, 2024: Leukemia Research
#24
JOURNAL ARTICLE
Soleyman Bafadam, Behnaz Mokhtari, Manoucheher Seyedi Vafaee, Zohreh Zavvari Oscuyi, Samira Nemati, Reza Badalzadeh
Ischaemic heart diseases (IHD) are among the major causes of mortality in the elderly population. Although timely reperfusion is a common treatment for IHD, it causes additional damage to the ischaemic myocardium known as ischaemia-reperfusion (IR) injury. Considering the importance of preventing reperfusion injuries, we aimed to examine the combination effect of mitochondrial transplantation (MT) and coenzyme Q10 (CoQ10 ) in myocardial IR injury of aged male rats. Seventy-two aged male Wistar rats were randomly divided into six groups: Sham, IR, CoQ10 , MT, combination therapy (MT + CoQ10 ) and vehicle...
March 13, 2024: Experimental Physiology
#25
REVIEW
Salim S Hayek, Vlad G Zaha, Carmel Bogle, Anita Deswal, Amelia Langston, Seth Rotz, Alexi Vasbinder, Eric Yang, Tochukwu Okwuosa
Hematopoietic stem cell transplantation can cure various disorders but poses cardiovascular risks, especially for elderly patients and those with cardiovascular diseases. Cardiovascular evaluations are crucial in pretransplantation assessments, but guidelines are lacking. This American Heart Association scientific statement summarizes the data on transplantation-related complications and provides guidance for the cardiovascular management throughout transplantation. Hematopoietic stem cell transplantation consists of 4 phases: pretransplantation workup, conditioning therapy and infusion, immediate posttransplantation period, and long-term survivorship...
March 11, 2024: Circulation
#26
JOURNAL ARTICLE
Miran Bezjak, Ivan Stresec, Branislav Kocman, Stipislav Jadrijević, Tajana Filipec Kanizaj, Miro Antonijević, Bojana Dalbelo Bašić, Danko Mikulić
BACKGROUND: The growing disparity between the rising demand for liver transplantation (LT) and the limited availability of donor organs has prompted a greater reliance on older liver grafts. Traditionally, utilizing livers from elderly donors has been associated with outcomes inferior to those achieved with grafts from younger donors. By accounting for additional risk factors, we hypothesize that the utilization of older liver grafts has a relatively minor impact on both patient survival and graft viability...
February 27, 2024: World Journal of Gastrointestinal Surgery
#27
JOURNAL ARTICLE
Michael J Sadowsky, Michael Matson, Prince P Mathai, Maradi Pho, Christopher Staley, Clayton Evert, Melissa Weldy, Alexander Khoruts
BACKGROUND: Fecal microbiota transplants can be administered orally in encapsulated form or require invasive procedures to administer liquid formulations. There is a need for an oral liquid formulation of fecal microbiota for patients who are unable to swallow capsules, especially if they require multiple, repeated administrations. AIMS: These studies were conducted to develop a protocol to manufacture an organoleptically acceptable powdered fecal microbiota formulation that can be suspended in a liquid carrier and used for fecal microbiota transplantation...
March 8, 2024: Digestive Diseases and Sciences
#28
JOURNAL ARTICLE
Xun-Hong Cao, Ze-Ying Fan, Ying-Jun Chang, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang, Xiang-Yu Zhao
AIMS: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for hematological malignancies. However, viral infections, particularly EBV infection, frequently occur following allo-HSCT and can result in multi-tissue and organ damage. Due to the lack of effective antiviral drugs, these infections can even progress to post-transplant lymphoproliferative disorders (PTLD), thereby impacting the prognosis. In light of this, our objective is to develop a prediction model for EBV infection following allo-HSCT...
March 6, 2024: Journal of Translational Medicine
#29
REVIEW
Alberto Mella, Ruggero Calvetti, Antonella Barreca, Giovanni Congiu, Luigi Biancone
Based on the current projection of the general population and the combined increase in end-stage kidney disease with age, the number of elderly donors and recipients is increasing, raising crucial questions about how to minimize the discard rate of organs from elderly donors and improve graft and patient outcomes. In 2002, extended criteria donors were the focus of a meeting in Crystal City (VA, USA), with a goal of maximizing the use of organs from deceased donors. Since then, extended criteria donors have progressively contributed to a large number of transplanted grafts worldwide, posing specific issues for allocation systems, recipient management, and therapeutic approaches...
March 6, 2024: Journal of Nephrology
#30
JOURNAL ARTICLE
Masatomo Ogata, Kiyomi Osako, Maho Terashita, Takamasa Miyauchi, Yuko Sakurai, Kazunobu Shinoda, Hideo Sasaki, Yugo Shibagaki, Masahiko Yazawa
BACKGROUND: Elderly living kidney donors (LKDs) are becoming increasingly important in countries with a high prevalence of living-donor kidney transplants and an aging society. This study explored the features of elderly LKDs, focusing on their subsequent outcomes. METHODS: This single-center, retrospective, observational study included eligible LKDs who donated their kidneys between April 2008 and July 2022. LKDs were categorized into an elderly (≥70 years at donation) or a non-elderly group (<70 years)...
March 4, 2024: Clinical and Experimental Nephrology
#31
JOURNAL ARTICLE
Mahek Garg, Justin Puckett, Sachin Kamal-Bahl, Monika Raut, Katherine Elizabeth Ryland, Jalpa A Doshi, Scott F Huntington
BACKGROUND: Little recent real-world evidence exists on overall survival, healthcare resource utilization (HCRU), and costs among R/R DLBCL patients treated with the combination of rituximab, gemcitabine, and oxaliplatin (R-GemOx), a widely-used regimen for patients ineligible for stem cell transplant due to age or comorbidities. PATIENTS AND METHODS: This retrospective analysis used 2014 to 2019 U.S. Medicare claims. Individuals aged ≥66 years with a new DLBCL diagnosis between October 1, 2015 and December 31, 2018 and continuous fee-for-service Medicare Part A, B, and D coverage in the 12 months pre- and postindex were followed to identify the sample of patients with evidence of R-GemOx treatment in the second-line (2L) or third-line (3L) setting...
February 9, 2024: Clinical Lymphoma, Myeloma & Leukemia
#32
JOURNAL ARTICLE
Yu Cao, Jie Zhao, Gang Feng, Zhen Wang, Jianghao Wei, Yang Xu, Chunbai Mo, Wenli Song
The effect of age on outcomes after simultaneous pancreas-kidney transplantation (SPK) among type II diabetes (T2DM) recipients remains inconclusive. This study aimed to analyze the relationship between the age at time of transplantation and mortality, graft loss and metabolic profiles of T2DM SPK recipients. A retrospective cohort consisting of T2MD SPK recipients in a single transplant center was established. The baseline clinical characteristics and outcomes were collected and analyzed based on the age groups divided by 55-year-old...
February 29, 2024: Diabetology & Metabolic Syndrome
#33
JOURNAL ARTICLE
Oana Ailioaie, Marie Essig, Hélène Levassort
Kidney disease, whether acute or chronic, is a particularly common condition in the elderly, due to its main risk factors, the prevalence of which increases with age, and the fact that recovery from acute tubular damage is slower. Wherever possible, treatment of renal failure should be anticipated and discussed with the patient as part of a shared medical decision. Numerous treatment options are available to ensure maximum integration into the patient's life and care plan: renal transplantation for the most robust patients, hemodialysis in a care facility or at home, peritoneal dialysis at home, or medical treatment without dialysis...
2024: Soins. Gérontologie
#34
JOURNAL ARTICLE
Xiuxiu Chen, Donghui Zhu, Renshan Ge, Zhijun Bao
Triphenyltin (TPT) is a widely used biocide known for its high toxicity to various organisms, including humans, and its potential contribution to environmental pollution. The aging process leads to progressive deterioration of physiological functions in the elderly, making them more susceptible to the toxic effects of environmental pollutants. This study aimed to investigate the mitigating effect of fecal transplantation in young mice on the toxicological impairment caused by TPT exposure. For the study, 18-month-old mice were divided into four groups with six replicates each...
February 27, 2024: Ecotoxicology and Environmental Safety
#35
REVIEW
Ahmed Adel Elsabagh, Maria Benkhadra, Ibrahim Elmakaty, Abdelrahman Elsayed, Basant Elsayed, Mohamed Elmarasi, Mohammad Abutineh, Nabeel Mohammad Qasem, Elrazi Ali, Mohamed Yassin
Chronic myeloid leukemia (CML), while traditionally a disease of the elderly, has recently risen in incidence among younger patients. Hence, fertility concerns have emerged considering the disease process and treatments, especially with the current scarce and conflicting recommendations. This review explores the impact of CML treatments including the first-line tyrosine kinase inhibitors (TKIs) and other treatments on male fertility in chronic myeloid leukemia (CML) patients. The aim of this review was to compile the available evidence on male fertility to ultimately tailor treatment plans for male CML patients for whom fertility and future chances for conception pose a concern...
February 15, 2024: Cancers
#36
JOURNAL ARTICLE
Dario Cattaneo, Alessandro Torre, Marco Schiuma, Aurora Civati, Giacomo Casalini, Andrea Gori, Spinello Antinori, Cristina Gervasoni
Pulmonary aspergillosis mainly affects elderly patients, patients with pulmonary complications, patients with hematological malignancies, organ transplant recipients, or critically ill patients. Co-morbidities may result in a high rate of polypharmacy and a high risk of potential drug-drug interaction (pDDI)-related antifungal azoles, which are perpetrators of several pharmacokinetic- and pharmacodynamic-driven pDDIs. Here, we report the results of the first 2-year study of an outpatient clinic focusing on the management of therapies in patients with pulmonary aspergillosis...
January 26, 2024: Journal of Fungi (Basel, Switzerland)
#37
REVIEW
Rengin Erdal, Gulnaz Arslan, Sedat Boyacioglu, Figen Ozcay, Adnan Torgay, Mehmet Haberal
In this study, our aim was to show the life expectancy according to donor age groups at 1, 3, 5, 10, 15, and 20 years after liver transplant in liver transplant recipients. In this retrospective study, we analyzed the survival rate of 236 patients who had liver transplant procedures between 1988 and 2021. The 5-year life expectancy of recipients with donors over age 50 years in the literature has been shown to vary between 50% and 80%. Little information could be found on life expectancy after 10, 15, and 20 years in other studies...
January 2024: Experimental and Clinical Transplantation
#38
JOURNAL ARTICLE
Bingjun Gao, Zhonghua Zhou, Junfei Chen, Shengling Zhang, Shaobin Jin, Weiwei Yang, Yinghan Lei, Kunyao Wang, Jinxu Li, Yan Zhuang
OBJECTIVE: Investigating the causal relationship between Lachnospiraceae and Appendicular lean mass (ALM) and identifying and quantifying the role of Aminopeptidase O Protein (AOPEP) as a potential mediator. METHODS: The summary statistics data of gut microbiota composition from the largest available genome-wide association study (GWAS) meta-analysis conducted by the MiBioGen Consortium ( n = 13,266). Appendicular lean mass data were obtained from the UK-Biobank ( n = 450,243)...
2024: Frontiers in Microbiology
#39
JOURNAL ARTICLE
Qinqin Pan, Xiao Ma, Yajie You, Yuejiao Yu, Su Fan, Xiaoyan Wang, Mengyuan Wang, Ming Gao, Guangming Gong, Kourong Miao, Jie Shen, Xiaoyu Zhou
BACKGROUND: With the development of Hematopoietic Stem Cell Transplantation (HSCT) technology, increasing numbers of elderly patients were undergoing allogeneic HSCT and elderly patients with hematologic malignancies could benefit most from it. Preformed donor-specific human leukocyte antigen (HLA) antibodies (DSA) were associated with graft failure in HLA-mismatched allogeneic HSCT and the absence of DSA was the main criterion of selecting the donor. Except for sensitization events such as transfusion, pregnancy or previous transplantation, ageing affects the humoral immune response both quantitatively and qualitatively...
February 20, 2024: Immunity & Ageing: I & A
#40
JOURNAL ARTICLE
Runguo Wu, Claire Williams, Junwen Zhou, Iryna Schlackow, Jonathan Emberson, Christina Reith, Anthony Keech, John Robson, Jane Armitage, Alastair Gray, John Simes, Colin Baigent, Borislava Mihaylova, Jane Armitage, Colin Baigent, Elizabeth Barnes, Lisa Blackwell, Rory Collins, Kelly Davies, Jonathan Emberson, Jordan Fulcher, Heather Halls, William G Herrington, Lisa Holland, Anthony Keech, Adrienne Kirby, Borislava Mihaylova, Rachel O'Connell, David Preiss, Christina Reith, John Simes, Kate Wilson, Michael Blazing, Eugene Braunwald, James de Lemos, Sabina Murphy, Terje R Pedersen, Marc Pfeffer, Harvey White, Stephen Wiviott, Michael Clearfield, John R Downs, Antonio Gotto, Stephen Weis, Bengt Fellström, Hallvard Holdaas, Alan Jardine, Terje R Pedersen, David Gordon, Barry Davis, Curt Furberg, Richard Grimm, Sara Pressel, Jeffrey L Probstfield, Mahboob Rahman, Lara Simpson, Michael Koren, Björn Dahlöf, Ajay Gupta, Neil Poulter, Peter Sever, Hans Wedel, Robert H Knopp, Stuart Cobbe, Bengt Fellström, Hallvard Holdaas, Alan Jardine, Roland Schmieder, Faiez Zannad, D John Betteridge, Helen M Colhoun, Paul N Durrington, John Fuller, Graham A Hitman, Andrew Neil, Eugene Braunwald, Barry Davis, C Morton Hawkins, Lemuel Moyé, Marc Pfeffer, Frank Sacks, John Kjekshus, Hans Wedel, John Wikstrand, Christoph Wanner, Vera Krane, Maria Grazia Franzosi, Roberto Latini, Donata Lucci, Aldo Maggioni, Roberto Marchioli, Enrico B Nicolis, Luigi Tavazzi, Gianni Tognoni, Jackie Bosch, Eva Lonn, Salim Yusuf, Jane Armitage, Louise Bowman, Rory Collins, Anthony Keech, Martin Landray, Sarah Parish, Richard Peto, Peter Sleight, John Jp Kastelein, Terje R Pedersen, Robert Glynn, Antonio Gotto, John Jp Kastelein, Wolfgang Koenig, Jean MacFadyen, Paul M Ridker, Anthony Keech, Stephen MacMahon, Ian Marschner, Andrew Tonkin, John Shaw, John Simes, Harvey White, Patrick W Serruys, Genell Knatterud, Gerard J Blauw, Stuart Cobbe, Ian Ford, Peter Macfarlane, Chris Packard, Naveed Sattar, James Shepherd, Stella Trompet, Eugene Braunwald, Christopher P Cannon, Sabina Murphy, Rory Collins, Jane Armitage, Louise Bowman, Richard Bulbulia, Richard Haynes, Sarah Parish, Richard Peto, Peter Sleight, Pierre Amarenco, K Michael Welch, John Kjekshus, Terje R Pedersen, Lars Wilhelmsen, Philip Barter, Antonio Gotto, John LaRosa, John Jp Kastelein, James Shepherd, Stuart Cobbe, Ian Ford, Sharon Kean, Peter Macfarlane, Chris Packard, Michele Roberston, Naveed Sattar, James Shepherd, Robin Young, Hiroyuki Arashi, Robert Clarke, Marcus Flather, Shinya Goto, Uri Goldbourt, Jemma Hopewell, G Kees Hovingh, George Kitas, Connie Newman, Marc S Sabatine, Gregory G Schwartz, Liam Smeeth, Jonathan Tobert, John Varigos, Junichi Yamamguchi
BACKGROUND: UK cardiovascular disease (CVD) incidence and mortality have declined in recent decades but socioeconomic inequalities persist. AIM: To present a new CVD model, and project health outcomes and the impact of guideline-recommended statin treatment across quintiles of socioeconomic deprivation in the UK. DESIGN AND SETTING: A lifetime microsimulation model was developed using 117 896 participants in 16 statin trials, 501 854 UK Biobank (UKB) participants, and quality-of-life data from national health surveys...
February 19, 2024: British Journal of General Practice
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
